News | October 06, 2024
Briefs: Aurobindo Pharma and Lupin
USFDA completes PAI of Lupin’s biotech facility in Pune
USFDA completes PAI of Lupin’s biotech facility in Pune
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Subscribe To Our Newsletter & Stay Updated
